YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer-Sabrina Martucci Johnson Chief Accounting Officer-MarDee J. Haring-Layton Full Conference Call Transcript O…
Earnings Call Insights: Daré Bioscience (DARE) Q2 2026 MANAGEMENT VIEW * "In June, we launched Flora Sync LF5, the first product in our DARE to RESTORE line." (CEO, President, Principal Financial Officer, Secretary & Director Sabrina Johns…
A featured menopause telehealth option is now available to women exploring DARE to PLAY™, advancing Daré’s strategy to build a trusted women’s health ecosystem spanning products, education and access to care Collaboration will expand Daré’…
Live video webcast on Tuesday, July 14th, at 4:00 PM ET Register here SAN DIEGO, July 09, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's h…
Earnings Call Insights: Daré Bioscience (DARE) Q1 2026 MANAGEMENT VIEW * "We will review our financial results, provide updates on our clinical pipeline and discuss the continued execution of our expanded business strategy" (Chief Accounti…
* Dare Bioscience press release [https://seekingalpha.com/pr/20453256-dare-bioscience-reports-full-year-2025-financial-results-and-provides-business-update] (DARE [https://seekingalpha.com/symbol/DARE]): FY GAAP EPS of -$1.20 beats by $0.4…
The following companies are expected to report earnings after hours on 03/26/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Argan, Inc. (AGX)is reporting for the quarter ending January 31, 2026. The buildi…
SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, will host…
(RTTNews) - Several biotech and healthcare stocks posted notable gains in after-hours trading on Friday, driven by regulatory developments, financing updates, and investor sentiment. Atossa Therapeutics, Inc. (ATOS) rose 12.98% to $0.69, u…
Daré Bioscience, Inc. SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world…
Earnings Call Insights: Daré Bioscience (DARE) Q3 2025 MANAGEMENT VIEW * CEO Sabrina Johnson stated that "Daré is at an inflection point. The third quarter of 2025 reflects the continued acceleration of our dual path strategy as we focus o…
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.55 per share a year ago. These figures are adjusted for non-recurring item…
DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product Revenue Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued Enrollment Multiple Grant-Funded…
Major earnings expected after the bell on Thursday include: * Applied Materials (AMAT [https://seekingalpha.com/symbol/AMAT]) * Virgin Galactic Holdings (SPCE [https://seekingalpha.com/symbol/SPCE]) * Nu Holdings Ltd. (NU [https://seekinga…
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.59 per share a year ago. These figures are adjusted for non-recurring item…
SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real solutions, will host a confe…
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.48 per share a year ago. These figures are adjusted for non-recurring items. This…
Earnings Call Insights: Daré Bioscience (DARE) Q2 2025 MANAGEMENT VIEW * Sabrina Martucci Johnson, CEO, stated that "Daré is at an inflection point. The second quarter of 2025 reflects the continued acceleration of our dual-path strategy a…
Key Points GAAP EPS loss of $0.45 beat the estimated loss of $0.58 for the quarter, reflecting lower operating expenses. GAAP revenue was negative $21,172, missing the positive $283,000 GAAP revenue estimate. Pipeline and product launches…
DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued Enrollment Multiple G…
Major earnings expected after the bell on Thursday include: * Applied Materials (AMAT [https://seekingalpha.com/symbol/AMAT]) * Bionano Genomics (BNGO [https://seekingalpha.com/symbol/BNGO]) * Nu Holdings Ltd. (NU [https://seekingalpha.com…
A first-of-its-kind solution for women’s arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 Collaboration leverages Rosy Wellnes…
A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth…
Zimmer Biomet (ZBH) signed a definitive agreement to acquire Monogram Technologies (MGRM) for a cash PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
SAN DIEGO, July 14, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced positive interim safety and e…
SAN DIEGO - Daré Bioscience, Inc. (NASDAQ:DARE), a biotechnology company with a market capitalization of $21.15 million, has received a $6 million non-dilutive funding installment to support the development of its contraceptive drug delive…
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced the receipt of a $6 million n…
Dare Bioscience, Inc. (NASDAQ:DARE) reported the results of its 2025 annual meeting of stockholders, which was reconvened Wednesday after an earlier adjournment due to lack of quorum. The information is based on a press release statement i…
SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that the company’s 2025 annua…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Boston Scientific (BSX) is a stock that can certainly grab the attention of many investors, but do its…
Creates commercial opportunity in the estimated up to $4.5 billion compounded hormone therapy market, enabling women to access an evidence-based solutionFour on-market products will accelerate revenue generation and provide path to profita…
Presentation will focus on corporate communications strategies for unveiling an innovative expanded business strategyDaré recently announced its new dual-path approach for its proprietary Sildenafil Cream formulation and is targeting avail…
Enables women to access a solution that they want and needCreates an opportunity to accelerate revenue generation from this proprietary formulation Daré expects to start recording revenue and cash flow in the 4th quarter of this year Confe…
DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management Essentially all cervical cancer cases worldwide are caused by…
In this article, we will be analyzing the age structures globally while covering the 30 countries with the lowest median age in the world. If you wish to skip our detailed analysis, you can move directly to the 5 Countries with the Lowest…
SAN DIEGO and MORRISVILLE, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Premier Research International, LLC, a global clinical research, product development, and c…